Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.
about
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandTreatment for leiomyosarcoma and leiomyoma in children with HIV infectionThe myth of equipoise in phase 1 clinical trialsThe genome of canarypox virusLong-term follow-up of study participants from prophylactic HIV vaccine clinical trials in AfricaDNA vaccines against human immunodeficiency virus type 1.Is there a role for plant-made vaccines in the prevention of HIV/AIDS?Human immunodeficiency virus vaccine trialsProtease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sitesRole of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens.Binding of HIV-1 gp120 to DC-SIGN promotes ASK-1-dependent activation-induced apoptosis of human dendritic cells.Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines.Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development.Effect of lysine to arginine mutagenesis in the V3 loop of HIV-1 gp120 on viral entry efficiency and neutralization.Recent advancement in flavivirus vaccine development.DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adultsUse of placebos in Phase 1 preventive HIV vaccine clinical trialsHIV Vaccine Trials Network: activities and achievements of the first decade and beyond.Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.Innate immune recognition of poxviral vaccine vectors.HIV-1 impairs human retinal pigment epithelial barrier function: possible association with the pathogenesis of HIV-associated retinopathy.Tunable, biodegradable gold nanoparticles as contrast agents for computed tomography and photoacoustic imaging.Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.Cytotoxic T-lymphocyte responses to canarypox vector-based HIV vaccines in HIV-seronegative individuals: a meta-analysis of published studies.Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development
P2860
Q21134955-708BD895-416E-44AD-B03F-4E6D7EA6A4D8Q24235435-91304B07-41EB-4094-8401-5772BD653974Q24569794-8E657C39-CD35-4AE1-8E11-127DA64A7DF8Q24630284-0F7137D2-0DAF-4688-A216-36F1FA8114F5Q28654629-1BCDE92C-E210-4800-A6C2-ACA480A59880Q30342130-65D32A53-E7C7-444A-9584-29DCA1795333Q30350670-4F09BDA2-1930-49C1-85D6-FC4ED4E5DFF6Q30424366-F298A6F3-E4EB-45F8-A55F-19B1888EE5BFQ33614461-40F2F38A-7148-4979-9D48-D8F0CE636EE0Q33780579-01381AC1-D309-4E62-9A50-4093695A1B01Q34116871-1DE71EA7-E8C4-48D1-8B8C-DE3937444957Q34574823-71B4475A-86CF-4859-9873-7F9D26CCA3C5Q35023762-59DDDD07-A100-48C1-844F-E05B59417AA8Q35073979-91982044-9D47-4699-8850-8615ACC14410Q35580330-C4496528-A72B-4383-BB09-5145219BB3BCQ35728621-8A259D6C-9C62-4648-B7ED-FA2A2FE965F9Q35940696-E6890A36-D8A3-4AF7-B1EE-EA7E9AA6F6D4Q36011214-940720A3-BD6A-4B49-991A-4FB1FB530AE8Q36464748-6796F320-65B8-451C-9EC3-D9766C6C5584Q37216571-3C6937FB-3952-4A57-AB3E-924B7AF27F99Q37221660-FD8ECD01-EFED-471E-AA38-A7AB47D43E98Q37785949-09745248-8E8D-48BA-8002-7735543891A7Q37944321-D2BDA3C1-514E-4A5D-B9C7-65B608C60F9FQ38993792-85BFD0B5-EC99-49C1-87BF-2F7456B5DDD8Q39670240-ED384460-FEC3-4ADB-B392-87852AB167D0Q40206378-C1E3ACEE-FBF3-4C27-A520-F5D9EC1521C0Q44647967-6E1ED52D-48CC-4C22-850E-7C6C3840E00BQ56993265-155E6DEA-D48E-4AA6-8F9B-62D54850737A
P2860
Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Long-term safety analysis of p ...... hase I and II clinical trials.
@en
Long-term safety analysis of p ...... hase I and II clinical trials.
@nl
type
label
Long-term safety analysis of p ...... hase I and II clinical trials.
@en
Long-term safety analysis of p ...... hase I and II clinical trials.
@nl
prefLabel
Long-term safety analysis of p ...... hase I and II clinical trials.
@en
Long-term safety analysis of p ...... hase I and II clinical trials.
@nl
P2093
P1433
P1476
Long-term safety analysis of p ...... hase I and II clinical trials.
@en
P2093
D N Lawrence
M C Keefer
NIAID HIV Vaccine Trials Network
P B Gilbert
P304
P356
10.1016/S0264-410X(03)00158-0
P407
P50
P577
2003-06-01T00:00:00Z